A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ECZTRA 2
- Sponsors LEO Pharma
- 02 Sep 2019 Status changed from active, no longer recruiting to completed.
- 16 Jul 2018 Planned End Date changed from 6 Nov 2019 to 1 Aug 2019.
- 16 Jul 2018 Planned primary completion date changed from 6 Nov 2019 to 1 Sep 2018.